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Abstract 
The complimentary ability of different noninvasive imaging technologies with therapeutic 
modalities can be used in tandem providing high-resolution and highly sensitive imaging of 
events at the molecular and cellular level providing a means for image-guided therapy. There 
is increasing interest in using porphyrin-based photosensitizers as theranostics to take ad-
vantages of their near-infrared fluorescent properties for imaging and their strong singlet 
oxygen generation abilities for photodynamic therapy. Here we report a targeted multimodal 
bacteriochlorophyll theranostic probe. This probe consists of a bacteriochlorophyll deriva-
tive, a pharmacokinetics modification peptide linker and folate for targeted delivery to folate 
receptor expressing cancer cells. We demonstrate its multimodal theranostic capability, its 
folate receptor targeting ability and its utility for both NIR fluorescence imaging and photo-
dynamic therapy purposes both in vitro and in vivo. 
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Introduction 
The  idea  of  using  multiple  modalities  in  con-
junction in the field of oncology has come into fruition 
over  the  past  decade.  The  complimentary  ability  of 
different  non-invasive  imaging  technologies  with 
therapeutic  modalities  can  be  used  in  tandem 
providing high-resolution and highly sensitive imag-
ing  of  events  at  the  molecular  and  cellular  level 
providing  a  means  for  image-guided  therapy,  also 
known as theranostics [1]. For example, fluorescence 
is exploited as a possible technique for image-guided 
surgical resection. Optical imaging provides real-time 
information about surgical margins, thereby, extend-
ing the surgeon‟s vision ensuring complete surgical 
resection of tumors [2-3]. To increase the contrast of 
malignant  tissues,  probe  development  with  high 
specificity, selectivity and stability is highly desirable 
for the imaging of disease. Furthermore, the field of 
photodynamic therapy (PDT) has seen an insurgence 
of fluorescence guided PDT due to the inherent mul-
tifunctional  nature  of  some  photosensitizers  (PS) 
which produce both fluorescence emission and singlet 
oxygen  when  excited  [4-7].  PDT  is  a  clinically  ap-
proved  cancer  treatment  combining  light-activated 
drugs  known  as  PS,  light  and  oxygen  [8-9].  Conse-
quently, tumor destruction results from the produc-
tion of cytotoxic singlet oxygen [8-9]. PS development 
is  important  as  accumulation  of  PS  dictates  which 
tissues  are  destroyed,  thus,  by  developing  PS  that 
better concentrate within target tissue, we increase the 
contrast within target tissue, increasing our ability to 
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detect and treat lesions while preserving healthy tis-
sue  during  therapy.  There  is  increasing  interest  in 
using  porphyrin-based  molecules  in  PDT  which  is 
advantageous  as  they  are  bifunctional  compounds 
with near-infrared fluorescent properties and effica-
cious PS for PDT [10-13].  
 
 
 
Figure 1. BPF schematic. There are three components to 
BPF: Multifunctional Bchl, a peptide linker and a targeting 
moiety (Folate). BPF is multi-modal: 1) Near-infrared flu-
orescence imaging and 2) PDT.  
 
 
Bacteriochlorophyll  (Bchl)  is  emerging  as  a 
powerful multifunctional porphyrin. Bchl is extracted 
from R. Sphaeroids and is the most widely distributed 
bacteriochlorin pigment [14]. It is a near-infrared PS 
with  750-850  nm  excitation  and  emission  profile 
making it highly attractive for optical imaging  [15]. 
Near-infrared  wavelengths  (650-900nm)  are  optimal 
for fluorescence imaging as they providedeeper tissue 
penetration due to the low tissue absorption and low 
autofluorescence  resulting  in  higher  signal-to-noise 
ratios [2]. Despite  its favorable characteristics, early 
Bchl studies demonstrated limited application in PDT 
and optical imaging due to its unstable nature. Many 
efforts have occurred to address the instability of Bchl 
including modification of the isocyclic ring [14, 16], 
serine stabilization [17], fluorinated stabilization [18], 
inserting  palladium  to  form  a  more  stable  complex 
(TOOKAD) [19] and incorporation into nanoparticles 
[15][20].  Regardless  of  the  stabilization  technique, 
Bchl  has  established  itself  as  an  ideal  bifunctional 
imaging and PDT agent, in particular, palladium-Bchl 
(TOOKAD) has been used in patients for PDT treat-
ment of prostate cancer  [21-22]. We report here the 
first targeted multimodal Bchl theranostic probe (BPF) 
that follows a similar strategy to our previously re-
ported pyropheophorbide-peptide-folate (PPF) probe 
[23].  Like  PPF,  BPF  consists  of  Bchl,  a  pharmacoki-
netics modification peptide linker [23] and folate for 
targeted delivery to FR-expressing cancer cells (Figure 
1). The key difference between BPF and PPF is that 
BPF is significantly red-shifted (λexcitation = 748nm and 
λemission  =  766nm),  making  it  ideally  suited  for 
near-infrared imaging of deeper seeded tumors. Here 
we demonstrate the multimodal theranostic capability 
of BPF, its FR targeting capability and its utility for 
both  NIR  fluorescence  imaging  and  photodynamic 
therapy purposes.  
Methods and Materials 
General  Materials:  The  activating  agents 
1-hydroxybenzotriazole  (HOBt)  and  (benzotria-
zol-1-yl)-N,N,N′,N′-tetramethyluronium  hexafluoro-
phosphate  (HBTU)  were  purchased  from  Sig-
ma-Aldrich  and  Novabiochem,  and  used  without 
further purification. The Rink amide resins and all the 
9H-fluoren-9-ylmethoxycarbonyl  (N--Fmoc)-protected 
amino  acids  were  purchased  from  Novabiochem. 
Bacteriopheophorbide  a  (Bchl  acid)  and  folate  suc-
cinimide (Folate-NHS) were synthesized by the pre-
vious described protocols [15, 23].  
General HPLC Methods: Reverse-phase analyt-
ical high performance liquid chromatography (HPLC) 
experiments were performed on a XBridge-C18 col-
umn (2.5 μm, 4.6 mm × 50 mm) using a Waters 2695 
controller with a 2996 photodiode array detector and 
a Waters ZQ mass detector. The conditions were as 
follows:  solvent  A)  acetonitrile;  solvent  B)  0.1%  tri-
fluoroacetic acid (TFA); gradient, from 20% A + 80% B 
to 100% A + 0% B in 12min; flow rate, 0.8 mL min-1. 
Synthesis  of  BPF: A peptide sequence with D 
amino  acid  backbone,  Fmoc-gd(OtBu)e(OtBu)vd 
(OtBu)gs(tBu)gk(Mtt), was synthesized on Rink resin 
using Fmoc chemistry protocol. After removing the 
last  Fmoc  group,  Bchl  acid  was  coupled  to  the 
N-terminal of the peptide on resin at room tempera-
ture ([Bchl acid/HOBt/HBTU/peptide 3:3:3:1]). The 
Bchl-peptide-resin was then treated with a cleavage 
cocktail  (TFA:  triisopropylsilane:  water  =  95:2.5:2.5) 
for 1h at room temperature to remove the resin and 
cleave  the  protected  groups.  The  acquired 
Bchl-peptide  (BP)  was  divided  into  two  parts.  One 
part was purified by HPLC and used as a folate-free 
control in following studies. The other part was con-Theranostics 2011, 1 
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jugated with folate-NHS according to the previously 
reported  protocol  [23].  The  acquired  Bchl-peptide- 
folate (BPF) was purified by HPLC (Figure 2A).The 
UV-visible  spectrum  of  BPF  was  measured  using  a 
Varian Cary 50 UV-visible spectrophotometer (Figure 
2B). BPF was prepared in DMSO at a concentration of 
1M. 
Cell  Lines  and  Culture  Conditions:  Epithelial 
carcinoma  cells,  KB  and  HT1080,  were  grown  and 
maintained  in  Minimum  Essential  Medium  Eagle 
(MEM)  media  supplemented  with  10%  fetal  bovine 
serum at 37 °C in an atmosphere of 5% CO2 in a hu-
midified incubator. 
In  vitro  PDT  efficacy:  Approximately  2  ×  104 
cells per well (200 µL) were seeded in Nunc Labora-
tory-TekIICC2 96-multiwell plates and incubated for 2 
days  at  37  °C  under  5%  CO2.  The  cell  media  was 
changed to folate-free Park Memorial Institute (RPMI) 
1640  media  24h  prior  to  treatment.  BPF  (5M)  was 
dissolved in 2% DMSO and 0.01% Tween-80 in 200uL 
of folate-free RPMI 1640 media and incubated with 
cells for 16h at 37 °C under 5% CO2. The cells were 
then rinsed with PBS, resuspended with 150 µL of the 
MEM  medium  and  illuminated  by  light.  The  light 
source consisted of a 740nm light box consisting of 48 
LED diodes (Roithner Lasertechnik, Vienna, Austria). 
The ﬂuence rate was 6.3 mW/cm2. Cell viability was 
then determined by means of the colorimetric MTT 
assay. Briefly, after illumination, the cells were incu-
bated at 37 °C under 5% CO2 for 24h. The medium 
was  removed  and  3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (Invitrogen) solution in 
medium (0.5 mg/mL, 150 µL) was added to each well 
followed by incubation for 2h under the same envi-
ronment. 150 µL of a 1:1 ratio of DMSO to 70% iso-
propanol in 0.1 M HCl (10% by weight, 100 µL) was 
then added to each well. The plate was agitated on a 
Spectra  Max  Plus  microplate  reader  (Molecular  De-
vices  Corporation)  for  5s  before  the  absorbance  at 
570nm at each well was taken. 
In vivo model: All animal studies were carried 
out  under  institutional  approval  (University  Health 
Network,  Toronto,  Canada).  Adult  athymic  female 
nude mice were inoculated subcutaneously with 2 x 
106 KB or HT1080 cells in 200 µL of PBS media on the 
right or left flank under general anesthesia (isofluo-
rane in oxygen). Animals were maintained in patho-
gen-free conditions in autoclaved microisolator cages 
in the MaRS Animal Resource Centre.  
In  vivo  optical  imaging  studies:  Mice  bearing 
KB (right flank) and HT1080 (left flank) tumors were 
used to compare the tumor uptake and folate receptor 
targeting capability of BPF versus BP. 25 nmol of BPF 
or BP was formulated in 150 μL of aqueous solution 
using 5 μL of DMSO and 1.5 μL of Tween80. When the 
tumor size reached 5-10 mm in diameter, mice were 
intravenously injected via tail vein with BPF (n=5) or 
BP  (n=5)  under  general  anesthesia.  Whole-body  in 
vivo fluorescent imaging was performed before and at 
multiple time points (10min, 3h, 5h, 24h and 48h) after 
injection (MaestroTM, CRi: 680nm excitation,  700nm 
longpass  detection,  autoexposure  integration  time, 
total  fluorescence  signals  normalized  by  exposure 
time and ROI area (total signal/(ms * pixels)). Com-
parison between two different probes was made using 
the two-sample homoscedastic student t-test with the 
level  of  significance  set  at  p  <0.05.  Comparison  of 
probe  uptake  over  time  was  made  using  a  paired 
student  t-test  with  the  level  of  significance  set  at  p 
<0.05. 
Ex vivo xenograft studies: KB and HT1080 tu-
mors were harvested from mice 48h following BPF or 
BP injection. Tumors were imaged (MaestroTM, CRi: 
680nm excitation,  700nm longpass detection, auto-
exposure integration time, total fluorescence signals 
normalized by exposure time and ROI area (fluores-
cent  signal/(ms  *  pixels))  and  weighed  in  order  to 
assess  the  tumor  uptake  of  BPF  vs.  BP  in  KB  vs. 
HT1080 xenografts. Ex vivo fluorescent signals were 
corrected  for  weight.  Comparison  between  two  dif-
ferent probes was made using the two-sample homo-
scedastic student t-test with the level of significance 
set at p <0.05. 
In vivo PDT efficacy: Mice bearing KB tumors 
were  intravenously  injected  with  50  nmol  of  BPF 
(n=5)  under  general  anesthesia.  BPF  uptake  was 
monitored  by  in  vivo  fluorescence  imaging  and  3h 
after injection PDT treatment was given to the tumor. 
Using a 740nm continuous wave pig tail diode laser, 
tumors were treated with a single PDT light dose of 
137 J using a surface irradiation of 0.785 cm2 and flu-
ence rate of 75 mW/cm2. The mice were then moni-
tored daily. A drug-free control animal was treated 
with the same light conditions without BPF. The con-
trol mouse was sacrificed after 7 days as the tumor 
size had reached experimental endpoint. 
Results 
 We  designed  the  first  prototype  targeted  Bchl 
probe based on the following principles: 1) Bchl is an 
effective  imaging  and  therapeutic  agent,  2)  the 
Caspase-3  peptide  sequence  with  D  amino  acid 
backbone is a stable linker and modulator improving 
the delivery efficiency of Bchl and 3) folate is an ef-
fective homing molecule targeting FR-expressing tu-
mors (Figure 1). On the basis of this design, we have 
synthesized  Bchl-gdevdgsgk(folate)  (BPF).  The  pep-
tide  sequence  was  synthesized  following  the  Fmoc Theranostics 2011, 1 
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solid  phase  peptide  synthesis  protocol  using  a  PS3 
peptide synthesizer. The Fmoc protecting group was 
removed  by  20%  piperidine  in  N,N-Dimethyl-
formamide  and  Bchl  acid  was  conjugated  to  the 
N-terminal of the peptide. The Bchl-peptide resin was 
then treated with a cleavage cocktail to remove the 
resin and protecting groups allowing the subsequent 
coupling with folate. The final product was purified 
by HPLC (Figure 2A) and characterized by UV-visible 
spectroscopy with special absorption at 357, 527 and 
748nm (Figure 2B) and ESI mass spectrometry (m/z 
calcd  for  C87H107N21O27  [M]+  1878.90,  found  939.48 
[M]2+ and 1879.16 [M]+, Figure 2C). With the purified 
BPF product, preliminary in vitro PDT studies were 
first  conducted  to  evaluate  the  photocytotoxicity  of 
BPF in FR expressing KB cells. KB cell viability was 
investigated after 16h incubation with 5 M of BPF in 
the  absence  and  presence  of  light  (Figure  2D).  The 
formulation  used  (DMSO  and  Tween-80)  was 
non-toxic to cells. Using 10 J/cm2 and 20 J/cm2 light 
doses and 5 M and 15 M BPF, a gradient in cell vi-
ability  was  seen  dependent  on  both  light  dose  and 
BPF concentration as expected (Figure 2D, and Sup-
plementary Material: Figure S1). A BPF concentration 
of 5  M with a light dose of 10 J/cm2 reduced cell 
viability to 70.8%1.9%. When the light dose was in-
creased to 20 J/cm2, cell viability was reduced to less 
than 34.7%9.3%. When the concentration of BPF was 
increased to 15 uM, cell viability was reduced to less 
than 30% and 5% for a 10 J/cm2 and 20 J/cm2 light 
dose respectively. This study demonstrates the PDT 
efficacy of BPF in vitro. 
 To validate the tumor specificity and FR medi-
ated uptake of BPF, BPF versus BP tumor uptake was 
evaluated in vivo with nude mice bearing KB (high FR 
expression) on their right flank and HT1080 (low FR 
expression) on their left flank. Prior to Bchl probe in-
jection,  minimal  autofluorescence  was  seen  in  the 
animals. After a 25 nmol intravenous injection of BPF 
(1.8mg/kg)  or  BP  (1.4mg/kg),  whole  body  fluores-
cence  was  detectable  within  10min  (Figure  3).
 
 
 
Figure 2. BPF Characterization: A) HPLC chromatogram at 748nm B) UV Absorbance spectra C) Molecular structure and 
the observed mass spectrum and D) in vitro PDT efficacy of 5μM BPF in KB (FR positive) cells using 10 J/cm2 and 20 J/cm2 
light doses. Data are expressed as mean values  SEM of three independent experiments, each performed in triplicate. 
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Figure 3. Spectral reflectance fluorescence images of tumor-bearing mice with KB (high FR expressing, right flank) and 
HT1080 (low FR expressing, left flank) xenografts. Mice were administered with 25 nmol (in 200 L) of A) BPF and B) BP and 
imaged i) 10min, ii) 3h, iii) 5h, iv) 24h, v) 48h post intravenous injection. The in vivo time dependent KB versus HT1080 tumor 
uptake of C) BPF and D) BP is quantified based on the average fluorescent signal (counts/sec*area). Data are expressed as 
mean values + SEM (n=5) where * indicates p <0.05. 
 
Within 3 h, strong fluorescence signal was de-
tectable in KB tumors in the animals injected with BPF 
and remained in KB tumors for 48h whereas only a 
weak  fluorescent  signal  was  detectable  in  HT1080 
tumors (Figure 3A and C). At all time points for the 
animals  administered  BPF,  the  fluorescent  signal  in 
KB tumors was significantly higher (p <0.05) than the 
fluorescent  signal  in  HT1080  tumors  (Figure  3C). 
Furthermore,  the  BPF  signal  in  HT1080  xenografts 
significantly decreased between 5h and 24h (p <0.05) 
while the BPF signal in KB xenografts did not signifi-
cantly  decrease  (p  >0.1).  Animals  injected  with  BP 
showed  strong  fluorescence  signal  in  both  KB  and 
HT1080 tumors but not until 5h (Figure 3B and D). BP 
accumulated in the tumors regardless of their FR ex-
pression  (Figure  3B  and  D).  BP  fluorescent  signals 
significantly  decreased  24h  after  injection  (p  <0.05). 
After 48h, animals were euthanized and tumors were 
harvested.  Ex  vivo  fluorescent  imaging  of  KB  and 
HT1080 tumors mirror the in vivo imaging. Again, BPF 
preferentially  accumulated  in  FR  expressing  KB  tu-
mors  significantly  greater  (p  <0.05)  than  in  HT1080 
tumors while there is no significant difference in the 
uptake  of  BP  between  KB  and  HT1080  xenografts 
(Figure 4). This demonstrates the FR specificity of BPF 
and the importance of folate as a tumor homing mol-
ecule. 
 The  in vivo  photocytotoxicity  of  BPF  was  then 
evaluated in mice bearing KB tumors on their right 
flank. The dose of BPF (3.6 mg/kg) was increased to 
twice  that  used  for  fluorescence  imaging  to  ensure 
PDT  efficacy,  however,  this  dose  of  3.6  mg/kg  is 
lower than the 5 mg/kg photosensitizer doses of Bchl 
analogs  (for  example,  TOOKAD)  used  in  previous 
xenograft PDT studies [24-26]. Three hours after an 
intravenous injection of BPF, using a 740nm CW laser 
at 75 mW/cm2 with a 1 cm in diameter surface irra-
diation, KB tumors were treated with a total light dose 
of 137 J. A drug free control animal was treated with 
the same conditions without the injection of BPF. The 
treated  tumor  in  animals  administered  BPF  became 
swollen  within  24h  and  within  48h  signs  of  tumor 
necrosis was evident (Figure 5A). All treated tumors 
in the mice injected with BPF (n=5) reduced in size 
within  two  weeks  and  30  days  after  PDT,  3  mice 
showed complete tumor regression without any signs 
of tumor regrowth (Figure 5A v and vi) and 2 animals 
showed small tumor regrowth most likely due to in-
efficient light treatment as a result of the difficulty in 
visualizing  light  at  740nm  to  ensure  complete  light 
delivery to the tumor site. In contrast, the tumor on 
the drug-free control animals continued to increase in 
size after PDT light treatment. Within 7 days, the tu-
mors were oversized (1.5 x 1.5 cm) and the animals 
were  sacrificed  (Figure  5B).  These  results  clearly 
demonstrate the tumor accumulation of BPF and its 
photodynamic ability to cause tumor regression.  Theranostics 2011, 1 
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Figure 4. A) Ex vivo fluorescent imaging of excised KB and HT1080 tumors from animals administered with 25 nmol of BPF 
or BP. B) Average fluorescent signal of ex vivo tumor uptake of BPF or BP in KB and HT1080 xenografts. Data are expressed 
as mean values + SEM (n=5) where * depicts statistical significance with a p <0.05. 
 
 
 
 
Figure 5. PDT efficacy in KB tumor-bearing mice (high FR expressing, right flank) 3h after an intravenous injection of A) 50 
nmol BPF or B) PBS (control) using a 137 J PDT light dose at i) pre PDT, ii) 24h post PDT, iii) 2 days post PDT, iv) 7 days post 
PDT, v) 24 days post PDT, vi) 32 days post PDT. (n=5) 
  i ii iii iv v vi
i ii iii iv
A
B
i ii iii iv v vi
i ii iii iv
A
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Discussion 
We  have  successfully  synthesized  and  charac-
terized  a  novel  targeted  multimodality  Bchl  probe 
(BPF)  with  efficient  optical  imaging  properties  and 
effective  PDT  capabilities.  In  vivo  optical  imaging 
studies confirmed the FR targeting specificity of BPF 
and  its  ability  to  be  retained  and  clearly  delineate 
FR-expressing tumors. It is evident that the conjuga-
tion of folate to BP changes its properties and tumor 
retention characteristics. Folate deflects the potential 
of Bchl‟s own non-specific affinity to cancer cells. In 
vitro PDT studies demonstrated BPF‟s photocytotoxi-
city  which  was  mirrored  in vivo  whereby  complete 
tumor  regression  was  achieved.  Although  a  16h 
drug-light interval was used in vitro, a 3h drug-light 
interval was used in vivo as the optical imaging stud-
ies  demonstrated  that  the  highest  BPF  uptake  oc-
curred at 3h. This is not surprising as probe uptake 
demonstrated in vitro rarely translates to similar up-
take characteristics in vivo. 
Fluorescence imaging is proving to be a power-
ful tool for cancer diagnostics and treatment. It has 
received much attention due to its ease of implemen-
tation,  operational  simplicity,  low  cost  and  recent 
development  of  novel  fluorescent  probes  [2,  4,  27]. 
The tumor targeting ability of BPF and its favorable 
excitation  and  emission  spectra  (λexcitation  =  748nm, 
λemission = 766nm) make it an attractive optical agent 
providing efficient tissue penetration of photons and 
minimal  background  autofluorescence.  The  optical 
imaging properties of BPF with its tumor selectivity 
may enable its use as an effective image guidance tool 
during surgical resection. BPF better delineates tumor 
margins  within  the  surgical  bed,  thereby  ensuring 
complete  tumor  resection  and  aid  in  the  in-
tra-operative detection of small metastatic lesions that 
are otherwise not visible. BPF could also be used as 
means to „clean up‟ the surgical bed following resec-
tion.  PDT  treatment  of  the  entire  surgical  bed 
post-resection could result in the eradication of any 
residual tumor mass and microscopic metastatic de-
posits, while preserving normal tissues.  
Recently,  interest  has  risen  in  using  positron 
emission tomography (PET) for image guided thera-
py. PET is attractive as it provides quantitative drug 
biodistribution,  effective  treatment  planning  and 
provides non-invasive deep tissue images, key char-
acteristics not achievable by optical imaging and/or 
PDT  [28].  Similar  to  optical  probes,  targeted  radio-
tracer development is an important key to increasing 
tumor specificity and sensitivity [29]. Thus, attempts 
have been made to exploit the tumor avidity of por-
phyrins by the incorporation of radioisotopes for tar-
geting PET probes [30-31]. However, as demonstrated 
by TOOKAD, Bchl itself is an excellent metal chelator 
forming  a  highly  stable  metallo-complex  making  it 
potentially  an  efficient  delivery  vehicle  of  radioiso-
topes. Of particular interest is copper-64 (64Cu) [32] as 
Cu-porphyrins  are  exceedingly  stable  to  demetalla-
tion, has patient-tested non-toxicity, have comparable 
64Cu  half-life  with  porphyrin  pharmacokinetics  and 
most  importantly,  64Cu-chelation  does  not  alter  the 
biodistribution of its host porphyrin [33-38]. Previous 
studies have demonstrated that the stability of Bchl is 
dependent  on  its  central  metal  where  the  Cu-Bchl 
metal complex is the most stable [19]. Thus, similar to 
how palladium stabilizes Bchl (TOOKAD), the inser-
tion of  64Cu into Bchl‟s porphyrin ring may further 
stabilize Bchl making 64Cu-BPF not only an effective, 
but  highly  stable,  PET  imaging  probe.  Preliminary 
experiments evaluated the feasibility of radiolabeling 
BPF  with  64Cu,  Supplementary  Material:  Figure  S2. 
Although we were able to radiolabel BPF with  64Cu 
following 64Cu-porphyrin labeling procedures that we 
recently reported [39], within 24h, some demetallation 
was observed, indicating an unstable metallporphyrin 
complex. Further studies  evaluating different radio-
chemistry methods for a more stable chelation of 64Cu 
to Bchl are currently underway. We also preliminarily 
explored the potential of 64Cu-BPF to accumulate and 
image FR positive tumors (Supplementary Material: 
Figure S3). As the radiolabeling chemistry of 64Cu-BPF 
needs to be further evaluated to ensure stable  64Cu 
chelation, PET imaging studies did not demonstrate 
ideal  tumor  delineation,  however,  some  64Cu-BPF 
tumor  accumulation  was  observed  (Supplementary 
Material: Figure S3). The appeal of introducing PET 
properties into BPF addresses many limitations cur-
rently faced by optical imaging including unlimited 
deep  tissue  penetration,  quantitative  biodistribution 
and  an  efficient  non-invasive  means  for  treatment 
planning. The complementary nature of PET and op-
tical imaging may provide a means to translate PET 
treatment planning to the surgical table using fluo-
rescence image guidance with a single probe. 
There  are  several  advantages  to  having  multi-
modal applications in a single probe as it ensures the 
same  pharmacokinetics  and  colocalization  of  the 
probe  for  all  applications.  This  is  highly  appealing 
especially  when  therapy  is  involved  as  additional 
stress on the body‟s blood clearance mechanisms is 
avoided which often accompanies administration of 
multiple doses of agents [27]. Thus, the use of a single 
agent dismisses any variability in the tumor uptake 
specificity, pharmacokinetics and pharmacodynamics 
of BPF. Small molecule multimodal probes, such as 
BPF, are attractive because they are typically cleared Theranostics 2011, 1 
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by the renal system avoiding any toxicity associated 
with long-term liver retention, have a fast clearance 
time and rapid diffusion through tissue [27, 40]. Sen-
sitivities for radiotracers and optical imaging probes 
are within the same range [41] and therefore, an at-
tractive combination. The multimodal nature of BPF 
provides complimentary information with regards to 
tumor delineation useful in image guidance as well as 
drug accumulation, pharmacokinectics and pharma-
codynamics which is particularly useful in determin-
ing the ideal drug-light interval in PDT treatments. 
This efficient PDT capability of BPF combined with its 
optical and potential PET imaging properties makes 
BPF  a  powerful  imaging  and  therapeutic  tool  that 
may boost the clinical benefits of hybrid technologies. 
Conclusion 
 Here  we  report  the  successful  synthesis  and 
characterization  of  a  novel  multimodal  FR  targeted 
optical imaging and  PDT  agent. All results demon-
strate the FR specificity of BPF as it only accumulates 
in FR expressing tumors in vivo and serves as an effi-
cient fluorescent imaging probe for the detection of 
FR  positive  tumors.  Furthermore,  BPF  caused  com-
plete  tumor  regression  in vivo  after  PDT  treatment. 
Therefore, BPF is not only a specific diagnostic probe 
for FR expressing tumors but also a promising thera-
peutic agent for FR positive cancers. BPF provides a 
more sensitive tumor detection strategy and its PDT 
therapeutic  ability  provides  a  “see  and  treat”  ap-
proach ensuring specific treatment of targeted sites. 
FR is overexpressed in a variety of epithelial cancers 
particularly in ovarian, head and neck, brain, breast, 
colon, renal and lung carcinoma with limited expres-
sion  in  normal  tissues  [42-43].  In  addition  to  the 
promise of FR as an oncologic biomarker, FR is also 
overexpressed  and  accessible  on  activated  macro-
phages (i.e. associated with many inflammatory dis-
eases) [42-43]. BPF may play an important role in the 
imaging and therapy of FR positive diseases such as 
rheumatoid arthritis, Crohn‟s disease, atherosclerosis, 
and organ transplant rejection [42]. We envision that 
BPF may be potentially useful for disease detection, 
image-guided  surgery  allowing  completeness  of  re-
section by “extending the  surgeon‟s vision” and/or 
with adjuvant PDT treatment to safely and effectively 
eradicate any post-resection residual tumor cells and 
eliminate  microscopic  deposits.  Finally,  the  folate 
homing molecule in BPF may be switched to another 
disease  specific  biomarker  providing  a  skeleton  for 
numerous targeted multifunctional Bchl probes that 
would allow for earlier diagnosis and more effective 
therapeutics.  
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